Analysts await NovoCure Limited (NASDAQ:NVCR) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.3 EPS, down 100% or $0.3 from last year’s $n/a per share.

At the moment 7 analysts are watching NovoCure Limited (NASDAQ:NVCR), 2 rate it “Buy”, 3 “Outperform”, 1 “Underperform”, 1 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 6 analysts have a mean sales target of 29.96 million. For the quarter ending Sep-16, 6 analysts have a mean sales target of 36.91 million whilst for the year ending Dec-16, 6 analysts have a mean target of 134.92 million.

In terms of earnings per share, 7 analysts have a -0.30 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 7 analysts have a -0.26 EPS mean target and for the quarter ending Sep-16 there are 6 estimates of -1.10 EPS.

The biggest institutional shareholders in NovoCure Limited include Volati Ltd which owns 8 million shares in the company valued at $171.86 million. T. Rowe Price Associates, Inc. is the second biggest holder with 3 million shares currently valued at 55.73 million whilst Fidelity SelectCo, LLC has 2 million shares valued at 23.02 million.

Total shares held by institutions as of the most recent company filings are 17,754,901 with a reported 256,003 bought and 0 sold. These holdings make up 20.83% of the company’s outstanding shares.

Currently insiders hold 148,114 shares in the business which makes up 0.18% of shares. The biggest holder currently is Mr. Asaf Danziger who owns 992,687 shares (1.18% of those outstanding), whilst Mr. Michael Ambrogi holds 334,084 (0.40% of shares outstanding) and Wilhelmus C. M. Groenhuysen holds 263,128 (0.31% of shares outstanding).

The stock increased 11.02% or $1.25 during the last trading session.